Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | TIMP3 | P35625 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | P2RY11 | Q96G91 | 8/20 | 0.85 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.85 |
| ▸ | MAPT | P10636 | 4/20 | 0.85 |
| ▸ | PKM | P14618 | 4/20 | 0.85 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.85 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.85 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.85 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.85 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.85 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.85 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.85 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392305 | 1.00 | RECQL (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| Suramin SCHEMBL3161 | 0.92 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| Suramin SCHEMBL29371906 | 0.92 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| Suramin SCHEMBL30312075 | 0.92 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| Suramin SCHEMBL29357785 | 0.92 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| Suramin SCHEMBL30552218 | 0.92 | P2RY11 (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| SCHEMBL3360329 | 0.92 | TIMP3 (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| SCHEMBL29381707 | 0.92 | TIMP3 (1.00) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| SCHEMBL29624871 | 0.91 | RECQL (0.82) | RECQLKMT2AHSD17B10TDP1TIMP3 | |
| SCHEMBL11582827 | 0.90 | P2RY11 (0.82) | RECQLKMT2AHSD17B10TDP1TIMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | claimed |
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | claimed |
| EP-4426280-B1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA ALEXANDRE (CH) | 2025-02-20 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| WO-2023111938-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | GURBA, Alexandre (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-11366121-B2 | Specific GNAI:GIV interaction screening assays, methods and compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-21 | — | — | US | disclosed |
| US-11366121-B2 | Specific GNAI:GIV interaction screening assays, methods and compositions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-1655032-B1 | USE OF THE P2X7 ANTAGONISTS o-ATP OR BBG FOR THE TREATMENT OF THE NEURODEGENERATIVE PHASE OF MULTIPLE SCLEROSIS | UNIV PAIS VASCO (ES) | 2009-10-07 | — | — | EP | disclosed |
| US-7485416-B2 | Screening methods for the identification of agents that inhibit SIRT1 Tat deacetylase activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1709206-A4 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | UNIV CALIFORNIA (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO (ES) | 2007-05-03 | — | — | US | disclosed |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO (ES) | 2007-05-03 | — | — | US | disclosed |
| EP-1709206-A2 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | The Regents of the University of California (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1655032-A1 | COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE AND DEMYELINATING DISEASES | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2006-05-10 | — | — | EP | disclosed |
| US-20050287597-A1 | Compositions and methods for modulating sirtuin activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-29 | — | — | US | disclosed |
| WO-2005062952-A2 | COMPOSITIONS AND METHODS FOR MODULATING SIRTUIN ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | TRPV1, ATP2A1, TRPM2 | RECQL 479/4885KMT2A 3763/4885HSD17B10 3726/4885 |
| US-20070099863-A1 | Compounds for the treatment of demyelinating and autoimmune diseases | P2RX2, P2RX3, P2RX1 | RECQL 902/4885KMT2A 3058/4885HSD17B10 4642/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | RECQL 1250/4885KMT2A 3984/4885HSD17B10 4508/4885 |
| US-11366121-B2 | Specific GNAI:GIV interaction screening assays, methods and compositions | GNAI1, GNAI3, GNAI2 | RECQL 4384/4885KMT2A 4614/4885HSD17B10 4490/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | RECQL 1250/4885KMT2A 3984/4885HSD17B10 4508/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | RECQL 1042/4885KMT2A 3482/4885HSD17B10 339/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | RECQL 1250/4885KMT2A 3984/4885HSD17B10 4508/4885 |
| US-20250057791-A1 | PROTECTION AGAINST ARTHROPOD PARASITES WITH PURINERGIC RECEPTOR (OPR) ANTAGONISTS | P2RX2, P2RX3, P2RX1 | RECQL 1702/4885KMT2A 4226/4885HSD17B10 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.